Drug-induced abnormalities of potassium metabolism

Polskie Archiwum Medycyny Wewnetrznej

Volumn 118, Issue 7-8, 2008, Pages 431-434

  Kokot, Franciszek ^a,c   Hyla Klekot, Lidia ^b  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b Center of Pediatrics and Oncology   (Poland)

^c Katedra i Klinika Nefrologii   (Poland)

Author keywords

Hyperkalemia; Hypokalemia; Potassium metabolism

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ALISKIREN; AMILORIDE; ANTIFUNGAL AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM SALT; CYCLOSPORIN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; GLUCOCORTICOID; HEPARIN; KETOCONAZOLE; LAXATIVE; LOOP DIURETIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; POTASSIUM CHLORIDE; SPIRONOLACTONE; TACROLIMUS; THIAZIDE DIURETIC AGENT; TRIAMTERENE;

ACIDEMIA; ASTHMA; CLINICAL FEATURE; DIABETES MELLITUS; HEART ARRHYTHMIA; HEMODIALYSIS; HUMAN; HYPERKALEMIA; HYPOKALEMIA; KIDNEY FAILURE; MUSCLE WEAKNESS; POTASSIUM METABOLISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; SYMPTOMATOLOGY; TUMOR LYSIS SYNDROME;

EID: 49249116427     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.442     Document Type: Review

References (17)

1. Kokot F. Zaburzenia gospodarki wodno-elektrolitowej i kwasowo-zasadowej w stanach fizjologii. Warszawa, PZWL, 2005.
2. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999; 341: 709-717.
3. Effectiveness of spironolactone added to an angiotensin - converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (The Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol. 1996; 76: 902-907.
4. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med. 2004; 351: 543-551.
5. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2002; 288: 2981-2997.
6. Giebisch G. Renal potassium channels: function, regulation and structure. Kidney Int 2001; 60: 436-445.
7. Rastegar A, Soleimani M. Hypokalaemia and hyperkalaemia. Postgrad M J. 2001; 77: 759-764.
8. Schmiedar RE. The potential role of prorenin in diabetic nephropathy. J Hypertens. 2007; 25: 1323-1326.
9. Danser AHJ, Batenburg WW, von Esch JHM. Prorenin and the (pro) renin receptor. Nephrol Dial Transplant. 2007; 22: 1288-1292
10. Gennari FJ, Segal AS. Hyperkalemia. An adaptive response in chronic renal insufficiency. Kidney Int. 2002; 22: 1-9.
11. Kim G-H, Han JS. Therapeutic approach to hypokalaemia. Nephron. 2002; 92 (Suppl 1): 28-32.
12. Aslam S, Friedman EA, Ifudu O. Electrocardiography is unreliable in detecting potentially lethal hyperkalaemia in haemodialysis patients. Nephrol Dial Transplant. 2002; 17: 1639-1642.
13. Gross P, Pistrosch F. Hyperkalaemia: again. Nephrol Dial Transplant. 2004; 19: 2163-2166.
14. Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med. 2004; 351: 585-592.
15. Kim H-J, Han S-W. Therapeutic approach to hyperkalaemia. Nephron. 2002; 92 (Suppl 1): 33-40.
16. Kamel KS, Wei C. Controversial issues in the treatment of hyperkalaemia. Nephrol Dial Transp. 2003; 18: 2215-2218.
17. De Palma JR. Hyperkalemia Rx. Dialysis and Transplantation. 2004; 33: 666-683.